Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Neoadjuvant Therapy
  • Niacinamide
  • Phenylurea Compounds
  • Quinolines

abstract

  • Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC.

publication date

  • October 20, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5569677

PubMed ID

  • 24019545

Additional Document Info

start page

  • 3791

end page

  • 9

volume

  • 31

number

  • 30